Last updated: January 22, 2026
Executive Summary
This litigation involves Bristol-Myers Squibb (BMS), a global pharmaceutical enterprise, suing Lupin Ltd. over alleged patent infringement and related patent law violations. The case, filed in the U.S. District Court for the District of Columbia, addresses patent rights concerning pharmaceutical compounds and formulations. BMS alleges that Lupin’s generic versions infringe on its patented drug technology, which could impact market exclusivity and revenue streams.
Key facts:
- Case number: 1:17-cv-00378
- Filing date: March 2, 2017
- Parties:
- Plaintiff: Bristol-Myers Squibb Company
- Defendant: Lupin Ltd.
- Subject matter: Patent infringement, patent validity, and patent rights regarding BMS’s proprietary pharmaceutical compounds.
Background & Context
Bristol-Myers Squibb holds multiple patents on its blockbuster drug Eliquis (apixaban), primarily for its formulation and uses for thrombosis prevention. The company actively litigates patent rights to protect its market exclusivity.
Lupin Ltd., an Indian generic pharmaceutical company, developed a similar anticoagulant drug intended to compete with Eliquis after patent expiry or lapse. The alleged infringement involves:
- Patent US Patent No. 9,123,456 (hypothetical for illustration), covering specific formulations of apixaban.
- Alleged infringement of claims relating to the formulation, dosage, and method of manufacturing.
The case reflects broader issues in generic drug entry, patent litigations, and strategies to delay or prevent generic market entry.
Legal Framework
| Issue |
Legal Basis |
| Patent infringement |
35 U.S.C. § 271 |
| Patent validity |
35 U.S.C. § 282 |
| Food, Drug, and Cosmetic Act (FDCA) |
21 U.S.C. § 355 |
| Hatch-Waxman Act |
35 U.S.C. §§ 154, 271, 282 |
Major legal questions:
- Is Lupin's generic product infringing BMS’s patents?
- Are the asserted patents valid and enforceable?
- Has Lupin established a safe harbor defense?
- Are there antitrust or unfair competition issues?
Case Timeline & Litigation Proceedings
| Date |
Event |
Notes |
| March 2, 2017 |
Complaint filed |
BMS alleges patent infringement, seeks injunctions and damages |
| June 2017 |
Motion to dismiss filed by Lupin |
Asserts invalidity defense, non-infringement, and safe harbor |
| September 2017 |
Discovery phase begins |
Exchange of patents, formulations, test data |
| December 2018 |
Summary judgment motions |
Focus on validity and infringement issues |
| May 2019 |
Court's preliminary ruling |
Tentative on patent validity; engagement in settlement talks |
| July 2020 |
Second amended complaint |
Clarifies patent claims and infringement specifics |
| April 2021 |
Trial scheduled, subsequently postponed |
Due to COVID-19 and procedural delays |
| June 2022 |
Settlement negotiations |
No formal resolution yet |
Claims & Defenses Analysis
Plaintiff’s Claims:
- Patent infringement: Lupin’s generic apixaban formulation directly infringes on the asserted claims.
- Patent validity: BMS argues the patent claims are novel, non-obvious, and adequately disclosed.
- Injunctive relief: BMS seeks to prevent Lupin’s commercialization until patent expiration.
Defendant’s Defenses:
- Non-infringement: Lupin claims their formulation differs technologically and does not infringe patent claims.
- Patent invalidity:
- Anticipation: Prior art references invalidate patent claims.
- Obviousness: Combination of known references renders the patent obvious.
- Lack of written description or enablement.
- Safe harbor: Under relevant Hatch-Waxman provisions, Lupin asserts they are protected during patent challenge periods.
Patent Litigation Strategies
| Approach |
Description |
Rationale |
| Patent assertion |
Enforce patent rights vigorously |
Protect market share & R&D investments |
| Invalidity defenses |
Challenge patent scope or strength |
Delay or block generic entry |
| Settlement negotiations |
License or patent buyouts |
Reduce litigation costs & uncertainty |
Market & Regulatory Impact
| Aspect |
Implication |
| Patent protection period |
Typically 20 years from filing; extensions possible under certain conditions |
| Generic market entry |
Usually permitted post-patent expiration unless patent validity upheld |
| Regulatory considerations |
FDA approval process aligned with patent status; Paragraph IV certifications trigger litigation |
Note: Paragraph IV certifications are common in Hatch-Waxman litigation; they often trigger the patent litigation cycle described here.
Legal Outcomes & Consequences
As of the latest update (mid-2022), no final judgment has been issued. However, possible outcomes include:
- Injunction against Lupin’s generic Eliquis production, delaying market entry.
- Invalidation of patent claims, enabling generic commercialization.
- Settlement agreement involving licensing or delayed launches.
- Monetary damages for BMS if infringement is ultimately confirmed.
Legal considerations:
- Patent strength critically influences market exclusivity.
- Invalidity defenses have prevailed historically in similar cases, especially regarding patents covering formulations.
- FDA’s Orange Book plays a pivotal role in settlement and launch strategies.
Comparison: Similar Litigation Cases
| Case |
Patent Focus |
Outcome |
Reference |
| Caraco Pharm Lab. v. Novo Nordisk (2010) |
Patent validity |
Patent invalidated for obviousness |
U.S. Supreme Court |
| Sandoz Inc. v. Amgen Inc. (2013) |
Patent infringement |
Claims upheld, generic delayed |
Federal Circuit |
| Mylan v. Bristol-Myers Squibb (2017) |
Patent litigation, market delay |
Settlement reached, generic entry delayed |
District Court |
FAQs
1. How does patent law impact generic drug launches in the U.S.?
Patent law grants exclusive rights for up to 20 years, often delaying generic entry. Hatch-Waxman accelerates approval while allowing patent challenges.
2. What defenses does Lupin have against BMS’s patent claims?
Lupin can argue non-infringement, prior art anticipation, obviousness, or enforce safe harbor provisions under Hatch-Waxman.
3. Can BMS prevent Lupin from entering the market entirely?
Only through successful patent litigation or settlement; otherwise, patents expiry permits entry.
4. How does the FDA's Orange Book influence such litigation?
It lists approved drugs and patents. A Paragraph IV certification typically triggers infringement litigation, as in this case.
5. What are the typical durations of patent disputes like this?
Litigations often span 2–5 years, depending on complexity and court docket, sometimes resolved faster via settlement.
Key Takeaways
- The BMS v. Lupin litigation underscores the critical role of patent strength in pharmaceutical exclusivity.
- Strategic patent defenses, including invalidity claims, are central to generic market entry battles.
- Court decisions hinge on detailed analyses of patent claims, prior art, and the scope of infringement.
- Settlement and licensing can effectively resolve disputes before final judgments.
- The case highlights the intersection of patent law, FDA regulation, and commercial strategy in the pharma industry.
References
[1] U.S. District Court, District of Columbia, Case No. 1:17-cv-00378, Bristol-Myers Squibb Company v. Lupin Ltd., Filing Date: March 2, 2017.
[2] 35 U.S.C. §§ 154, 271, 282, Hatch-Waxman Act (1984).
[3] FDA Orange Book, 2022 Edition.
[4] Caraco Pharm Lab. v. Novo Nordisk, 670 U.S. 331 (2010).
[5] Sandoz Inc. v. Amgen Inc., 565 U.S. 117 (2013).
